As part of a research collaboration launched in 2014, Boehringer Ingelheim and Anthem have partnered to study people with chronic obstructive pulmonary disease in real-world settings to assess how commonly-prescribed drugs may reduce the occurrence of COPD exacerbations.
The team, which also includes Anthem’s outcomes research subsidiary HealthCore, plans to investigate whether adding an inhaled corticosteroid to a LAMA-LABA combination provides a meaningful benefit – a question under debate in the respiratory space.
Get the full story at our sister site, Drug Delivery Business News.
